指南与共识心血管MR

心脏磁共振成像与一级预防植入式心律转复除颤器治疗:当前推荐与未来方向

Cardiac magnetic resonance imaging and primary prevention implantable cardioverter defibrillator therapy: current recommendations and future directions.
指南 / 共识 · J Cardiovasc Med (Hagerstown) · 2018-01-01

本文综述心脏磁共振(CMR)在一级预防植入式心律转复除颤器(ICD)治疗中的应用证据与未来前景。当前指南主要依据左心室射血分数(LVEF)低于35%确定预防性ICD适应证,但LVEF单独不足以理想分层心律失常风险。延迟钆增强CMR可准确识别和定量心肌纤维化,多项研究显示其较LVEF能更好分层心律失常风险;联合临床危险因素、生物标志物(N末端B型利钠肽原和高敏C反应蛋白)与CMR发现可能更有效预测心律失常风险。

要点

  • 延迟钆增强CMR可准确识别和定量心室心肌纤维化,多项研究显示其较LVEF能更好分层心律失常风险。
  • 当前指南预防性ICD适应证主要基于LVEF低于35%,但LVEF单独不是理想的风险分层参数。
  • 联合临床危险因素、N末端B型利钠肽原和高敏C反应蛋白与CMR发现可能更有效预测心律失常风险。

核心结论

  • 延迟钆增强CMR可准确识别和定量心室心肌纤维化,多项研究显示其较LVEF能更好分层心律失常风险。
  • 联合常规临床危险因素和生物标志物(N末端B型利钠肽原和高敏C反应蛋白)与CMR发现可能更有效预测心律失常风险。
  • 将应变技术应用于CMR以及T1 mapping等新组织特征指数可能预测快速性心律失常的发生。

研究设计与样本

  • 综述,旨在提供CMR用于一级预防ICD治疗的最先进证据和未来展望。

关键影像表现/征象

  • 延迟钆增强CMR可准确识别和定量心室心肌纤维化。
  • 心肌纤维化是恶性室性心律失常和心源性猝死的基质。
  • 心律失常风险主要取决于心肌组织病理学特征和电生理特性,这些在很大程度上不被左心室收缩功能反映。

诊断标准与关键数值

  • 当前指南预防性ICD适应证主要基于左心室射血分数(LVEF)低于35%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

: Implantable cardioverter defibrillators (ICDs) have proven to be the most effective preventive therapy of sudden cardiac death (SCD). Based on current guidelines, the indication for prophylactic ICD therapy is primarily based on a left ventricular ejection fraction (LVEF) less than 35%. However, patients with low LVEF may never have an arrhythmic event while patients with normal to moderately reduced LVEF, who are traditionally felt to be at lower risk, can experience SCD. Therefore, LVEF alone is not an ideal risk stratification parameter to determine ICD therapy. The arrhythmic risk depends mainly on myocardial histopathologic features and electrical properties, which are largely not reflected by left ventricular systolic performance. In addition, several studies demonstrated that the presence of myocardial fibrosis represents a substrate for malignant ventricular arrhythmias and SCD. Cardiac MRI with late gadolinium enhancement is a refined technique able to accurately identify and quantify ventricular myocardial fibrosis and numerous studies demonstrated its ability to better stratify arrhythmic risk compared with LVEF. Recently, the combination of conventional clinical risk factors and biomarkers, namely N-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein, with cardiac MRI (CMR) findings is proving to more effectively predict arrhythmic risk. Moreover, the application of strain technique to CMR and new tissue characterization indices such as T1 mapping represents an attractive possibility to predict the occurrence of tachyarrhythmia. The aim of this review is to provide state-of-the-art evidence and future perspectives on the use of CMR for primary prevention ICD therapy.

来源:J Cardiovasc Med (Hagerstown),查看原文。版权归原作者所有。

引用

  1. Guaricci AI, De Santis D, Rabbat MG, et al. Cardiac magnetic resonance imaging and primary prevention implantable cardioverter defibrillator therapy: current recommendations and future directions. J Cardiovasc Med (Hagerstown). 2018. PMID: 29561311. doi:10.2459/JCM.0000000000000650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。